Private
Results from non-human primate testing of a Soligenix, Inc.-developed Bivalent Thermostabilized Filovirus vaccine, released this week, suggested 100 percent protection provided against the Sudan ebolavirus among dosed non-human primates.
The single vial vaccine is meant to target both the... Read More »
Argentum Medical, a Geneva, Ill.-based medical device company, announced Tuesday that the U.S. Food and Drug Administration (FDA) had granted its Silverlon Wound Contact, Burn Contact Dressings a Breakthrough Device designation.
The FDA’s Breakthrough Device Program creates a pathway for... Read More »
A 13-10 vote by the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) set the stage for recommending Emergency Use Authorization of the Merck and Ridgeback Biotherapeutics oral COVID-19 antiviral molnupiravir this week.
The narrow backing followed a... Read More »
Moving quickly to address concerns raised by the Omicron COVID-19 variant, following its discovery last week, INOVIO announced it will evaluate two of its COVID-19 DNA vaccine candidates against the variant and has begun pre-clinical development of another specifically tailored to it.
Omicron... Read More »
Oshkosh Corporation officials said a subsidiary of the company, Oshkosh Defense, has secured an Army contract totaling $591.6 million for 1,669 Joint Light Tactical Vehicles (JLTV).
The contract, which was awarded via the Army Contracting Command – Detroit Arsenal (ACC-DTA), includes 868... Read More »
Northrop Grumman Corporation has secured a $153 million Navy contract to produce AGM-88E2 Advanced Anti-Radiation Guided Missiles (AARGM) for the Navy and German Air Force.
“As threats continue to evolve, AARGM remains an affordable solution to continue protecting the Navy and our allies with... Read More »
Results of a study on molnupiravir, an investigational oral antiviral developed by Merck and Ridgeback Biotherapeutics for use against COVID-19, showed this week that the drug cuts the risk of hospitalization or death by approximately 3 percent.
The trial of 1,433 participants focused on those... Read More »
Moderna announced last week a strategy for addressing the new Omicron variant of COVID-19, including a new booster vaccine and studies of boosters that have already anticipated its mutations.
The rushed strategy announcement came in the wake of closing borders and the World Health... Read More »
The World Health Organization (WHO) COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) recently reached a joint licensing agreement with the Spanish National Research Council (CSIC) for a non-exclusive COVID-19 serological antibody test.
The CSIC-developed test, to be... Read More »
A new report from the CommuniVax Coalition has found that while progress has been made regarding equity in the COVID-19 vaccination campaign, more work is needed.
Led by the Johns Hopkins Center for Health Security at the Bloomberg School of Public Health and the Department of Anthropology at... Read More »
Building on the success of its COVID-10 vaccine testing network to date, the Coalition for Epidemic Preparedness Innovations (CEPI) announced this week that it will expand its centralized testing capabilities to the development of vaccines for other epidemic and pandemic diseases.
CEPI’s... Read More »
Huntington Ingalls Industries announced that the company's Ingalls Shipbuilding division has received a $113.6 million Navy contract modification for the
Amphibious Assault Ship LHA 9.
The contract would enable long-lead-time material and advance procurement activities, bringing the total... Read More »
The Coalition for Epidemic Preparedness Innovations (CEPI) committed another $36.9 million to expand a contract with Clover Biopharmaceuticals and support the development of its COVID-19 vaccine candidate, SCB-2019, for use as a booster.
The new injection of funding increases CEPI’s investment... Read More »
The Biden administration announced an agreement with Pfizer Inc. last week that will provide 10 million courses of the company’s COVID-19 oral antiviral Paxlovid, pending Emergency Use Authorization or approval by the United States Food and Drug Administration (FDA).
“This promising... Read More »
Lockheed Martin recently announced that efforts to accelerate the production of its most advanced air defense missile have resulted in a milestone achievement.
Citing response to a government request last year, Lockheed Martin said it has completed production of its 1000th PAC-3 Missile Segment... Read More »
The U.S. government added to its supplies of COVID-19 treatments this week with the announcement of $1 billion worth of new deals to bring GlaxoSmithKline plc and Vir Biotechnology, Inc.’s sotrovimab into its stocks.
The agreements were clinched after final data was released from the COMET-ICE... Read More »
According to updates from AstraZeneca, the company and its partners managed to provide 2 billion doses of its COVID-19 vaccine to more than 170 countries within 11 months of its first approval and a little more than 18 months after AstraZeneca partnered with Oxford University on... Read More »
Dosing of the first volunteers for a Phase 1b clinical trial of Ebola vaccine candidate INO-4201 began this week to assess whether the vaccine could function as a booster for healthy, previously vaccinated patients.
The latest study followed positive results from pre-clinical and Phase 1 trials... Read More »
The United Nations-backed Medicines Patent Pool (MPP) gained access to Pfizer Inc.’s COVID-19 oral antiviral treatment candidate PF-07321332 this week, enabling the organization to produce and distribute the drug to generic sub-licensers for greater global access.
MPP intends to increase... Read More »
Northrop Grumman recently attained a Ground Based Strategic Deterrent (GBSD) first-stage solid rocket motor manufacturing milestone by successfully executing the first insulation and case wind processes.
“Working closely with the Air Force and nationwide team of industry partners, we continue... Read More »
National Security Agency (NSA) recently announced a partnership with the National Cryptologic Foundation to strengthen domestic cybersecurity education and cybersecurity job possibilities.
The collaboration is expected to promote a deeper understanding of prior domestic cryptologic successes;... Read More »
Data from the latest global survey on implementation of the Global Action Plan on addressing antimicrobial resistance (AMR) showed that more countries than ever are determined to fight AMR, but also major setbacks caused by the COVID-19 pandemic.
Of the 163 countries that responded to the survey... Read More »
A new effort by the COVAX Facility -- the COVAX Humanitarian Buffer -- received a shot in the arm this week through a new agreement with Johnson & Johnson, which will bring its single-shot COVID-19 vaccine to bear to help approximately 167 million displaced people around the world.
COVAX -- the... Read More »
The Department of Homeland Security (DHS) Countering Weapons of Mass Destruction Office (CWMD) has awarded a contract to Smiths Detection to provide 110 radiation portal monitors (RPM).
The RPMs would be deployed across land border crossings throughout the country. The passive checkpoints... Read More »
The United States federal government exercised two options on contracts with Merck and Ridgeback Biotherapeutics this week to purchase an additional 1.4 million courses of the investigational oral antiviral molnupiravir for use against COVID-19.
This deal will amount to approximately $1 billion... Read More »
With approval from the U.S. Food and Drug Administration (FDA) now in hand, INOVIO intends to proceed with a Phase 3 segment of its INNOVATE trial for the COVID-19 vaccine candidate INO-4800 in the United States.
Authorization followed a partial clinical hold on the candidate, while the FDA... Read More »
For at least eight months following a single dose, the REGEN-COV COVID-19 drug cocktail developed by Regeneron Pharmaceuticals, Inc. could provide affiliated risk reductions of 81.6 percent, according to a new analysis of a Phrase 3 trial.
That trial, jointly run by Regeneron and the National... Read More »
MSA Safety Inc. earned a $4 million contract from the U.S. Department of Health and Human Services (HHS) last week to produce elastomeric air-purifying respirators to be added to the Strategic National Stockpile (SNS).
The MSA’s Advantage 290 Air-Purifying Respirator (APR) consists of a... Read More »
Interim data from Pfizer Inc.’s novel COVID-19 antiviral candidate, PAXLOVID, revealed an oral treatment with the ability to cut the risk of hospitalization and death by as much as 89 percent among adult patients.
These results, pulled from the randomized Phase 2/3 EPIC-HR (Evaluation of... Read More »
On Wednesday, the U.S. Department of Homeland Security (DHS) Science and Technology Directorate (S&T) announced it had selected Northeastern University to lead a consortium of U.S. academic institutions for a new Center of Excellence for Engineering Secure Environments from Targeted Attacks... Read More »
The antiviral Molnupiravir became the first oral treatment for COVID-19 to receive authorization this week, winning approval from the U.K.’s Medicines and Healthcare Products Regulatory Agency for treatment of mild-to-moderate COVID-19 cases in adults.
Specifically, users must have had at... Read More »
The World Health Organization (WHO) made its eighth emergency use listing (EUL) for a COVID-19 vaccine this week, granting that honor to Bharat Biotech’s COVAXIN.
COVAXIN is formulated from an inactivated SARS-CoV-2 -- the virus that causes COVID-19 -- antigen. Use of the vaccine by adults was... Read More »
As world leaders gather in Glasgow for the UN Climate Change Conference, COP26, a new global partnership has formed to focus on the impact of climate change on terrorism, the group said Tuesday.
The National Consortium for the Study of Terrorism and Responses to Terrorism (START), Pool Re... Read More »
A Q2 Solutions Co., Ltd. lab facility in Beijing, China, became the first East Asian lab to join the Coalition for Epidemic Preparedness Innovations’ (CEPI) centralized COVID-19 lab network this week.
“I am delighted to today welcome Q2 Solutions’ facility in Beijing to this group of... Read More »
The failures, successes, and lessons learned from the rollout of COVID-19 vaccines should be incorporated immediately into future pandemic vaccine planning if the world hopes to avoid the delays and pitfalls of the modern ecosystem, according to a new report from the Johns Hopkins Center for Health... Read More »
